CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, today announced the oral presentation of “Phase II/III clinical results of IL-15RαFc superagonist N-803 ...
Please provide your email address to receive an email when new articles are posted on . Bacillus Calmette-Guérin, or BCG, is highly effective at treating and preventing recurrence of early-stage ...
QUILT 3.032 study completes planned enrollment of BCG unresponsive non-muscle invasive bladder cancer CIS cohort with 59% probability of patients maintaining complete response for at least 12 months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback